BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. BioCryst Pharmaceuticals, Inc.

Keep Reading →